Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 23

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 23
---
 | $ | 1,385 | ​ | ​ | ​ | ​             | $ | 1,620 | ​ | ​ |
| Audit-Related Fees | ​ | ​ | ​                      | ​ |     — | ​ | ​ | ​ | ​             | ​ |     — | ​ | ​ |
| Tax Fees(2)        | ​ | ​ | ​                      | ​ | 1,327 | ​ | ​ | ​ | ​             | ​ |   513 | ​ | ​ |
| All Other Fees(3)  | ​ | ​ | ​                      | ​ |     5 | ​ | ​ | ​ | ​             | ​ |     5 | ​ | ​ |
| Total Fees         | ​ | ​ | ​                      | $ | 2,717 | ​ | ​ | ​ | ​             | $ | 2,138 | ​ | ​ |

(1) For the years ended December 31, 2024 and 2023, this category represents fees for professional services provided in connection with the audit of our financial statements, review of our quarterly financial statements, and audit services provided in connection with other regulatory filings for which only the independent registered public accounting firm can reasonably be expected to provide. (2) For the years ended December 31, 2024 and 2023, this category represents fees related to tax consulting and planning services. (3) For the years ended December 31, 2024 and 2023, this category represents subscription fees for online research tool. Pre-Approval of Audit and Non-Audit Services Consistent with requirements of the Exchange Act, applicable SEC rules and the Public Company Accounting Oversight Board regarding auditor independence, our audit committee is responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our audit committee (or the chair if such approval is needed on a time urgent basis) pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services. All services rendered by Ernst & Young LLP for the years ended December 31, 2024 and 2023 were pre-approved by our audit committee. Resolution to be Voted Upon An ordinary resolution, being a simple majority of the votes duly cast at the Annual Meeting, is required to ratify the appointment of Ernst & Young LLP as our independent registered public accounting

15

TABLE OF CONTENT